283 related articles for article (PubMed ID: 38331870)
1. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
Trabolsi A; Arumov A; Schatz JH
Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
3. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM; Nowakowski GS; Wang Y
Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
[TBL] [Abstract][Full Text] [Related]
4. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
Jeyakumar N; Smith M
Front Immunol; 2022; 13():887866. PubMed ID: 35663947
[TBL] [Abstract][Full Text] [Related]
5. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
Del Toro-Mijares R; Oluwole O; Jayani RV; Kassim AA; Savani BN; Dholaria B
Br J Haematol; 2023 Apr; 201(1):15-24. PubMed ID: 36709623
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
7. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
González Barca E
Front Immunol; 2022; 13():909008. PubMed ID: 35928819
[TBL] [Abstract][Full Text] [Related]
8. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
9. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma.
Cassanello G; Luna de Abia A; Falchi L
Oncoimmunology; 2024; 13(1):2321648. PubMed ID: 38445082
[TBL] [Abstract][Full Text] [Related]
10. The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Nuvvula S; Dahiya S; Patel SA
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):362-372. PubMed ID: 34922844
[TBL] [Abstract][Full Text] [Related]
11. Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma.
Duarte C; Kamdar M
Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e390802. PubMed ID: 37098236
[TBL] [Abstract][Full Text] [Related]
12. Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas.
Major A; Kamdar M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):370-381. PubMed ID: 38066907
[TBL] [Abstract][Full Text] [Related]
13. Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era.
Atallah-Yunes SA; Robertson MJ; Davé UP; Ghione P; Perna F
Front Immunol; 2022; 13():901365. PubMed ID: 35720352
[TBL] [Abstract][Full Text] [Related]
14. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
[TBL] [Abstract][Full Text] [Related]
15. How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells.
Nagler A; Perriello VM; Falini L; Falini B
Br J Haematol; 2023 May; 201(3):396-410. PubMed ID: 36916189
[TBL] [Abstract][Full Text] [Related]
16. Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy.
Ababneh HS; Abramson JS; Johnson PC; Patel CG
Radiother Oncol; 2022 Oct; 175():65-72. PubMed ID: 35952976
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
Westin JR; Kersten MJ; Salles G; Abramson JS; Schuster SJ; Locke FL; Andreadis C
Am J Hematol; 2021 Oct; 96(10):1295-1312. PubMed ID: 34310745
[TBL] [Abstract][Full Text] [Related]
18. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
19. Treatment strategies for patients with diffuse large B-cell lymphoma.
Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U
Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930
[TBL] [Abstract][Full Text] [Related]
20. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
Watkins MP; Bartlett NL
Expert Opin Investig Drugs; 2018 Jul; 27(7):601-611. PubMed ID: 29940805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
